BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and ... ( Alliance Aims to First Develop Powerf...)

HOME >> BIOLOGY >> TECHNOLOGY

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

Date:5/4/2009

Alliance Aims to First Develop Powerful Tools for Detecting Ovarian Cancer Earlier

FRANKLIN LAKES, N.J. and MALVERN, Pa., May 4 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development and supply agreement for oncology diagnostic assays.

Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics' cancer biomarkers for use on BD's multiplex testing platform. The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio Diagnostics also grants BD, through its BD Diagnostics - TriPath platform, access to its other cancer biomarkers for inclusion in future multiplex diagnostic products.

"BD is investing in the development of tools and technologies essential for biomarker-guided cancer care. We believe that biomarker testing in a multiplex format can provide clinicians with a powerful toolset for detecting cancer at an earlier stage, which could allow them to begin treatment sooner and improve outcomes," said Wayne Brinster, Vice President and General Manager for Women's Health and Cancer, BD. "By incorporating Fujirebio Diagnostics' cancer biomarkers within our own cancer diagnostics development program, we believe that we are poised to provide clinicians with innovative diagnostic tools for improved patient management and contribute to BD's growth in cancer diagnostics."

"This alliance with BD is an excellent strategic fit for Fujirebio Diagnostics' business," said Paul Touhey, President and Chief Executive Officer, Fujirebio Diagnostics. "It will increase the use of HE4 as a tool in monitoring ovarian cancer and allow Fuji
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
2. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
3. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
4. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
5. Allegro Diagnostics Expands Board and Executive Team
6. Frost & Sullivan: In Vitro Diagnostics Market
7. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
8. Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation
9. Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System
10. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
11. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics

Post Your Comments:

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and ...( Alliance Aims to First Develop Powerf...)